Novo Nordisk shares are trading lower after the company announced it will no longer be working with Hims & Hers Health and it will not provide it direct access to Wegovy via NovoCae Pharmacy.

-2.41%

Novo Nordisk A/S Sponsored ADR Class B

NVO

0.00

Novo Nordisk shares are trading lower after the company announced it will no longer be working with Hims & Hers Health and it will not provide it direct access to Wegovy via NovoCae Pharmacy.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

'Lilly Drops CVS Drug Plan for Workers After Novo Deal' - Bloomberg

Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

Cigna Exec Says It Is Working With Novo, Lilly On Changes In GLP-1 Drug Prices After White House Deal

Korro Bio Says Effective Nov 11, Co & Novo Nordisk Amend Collaboration Agreement; Co & Novo Nordisk Pause Agreement For 12 Months; Agreed To Wind-Down Its Research And Development Activities In Connection With The License Agreement

Does Recent Drug Approval News Signal Opportunity in Novo Nordisk for 2025?

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Korro Bio Early Trial Results Fall Short; Stock Hits New Low